Enterprise Value

1.07B

Cash

83.25M

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.08%

Institutional Own.

77.31%

Qtr Updated

09/30/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Juxtapid/Lojuxta (lomitapide) Details
HoFH (Homozygous Familial Hypercholesterolemia)

Approved

Quarterly sales

Myalept (metreleptin injections) Details
GL (Generalized Lipodystrophy)

Approved

Quarterly sales

Oleogel-S10 (AP101) Details
EB (Epidermolysis bullosa), JEB (junctional epidermolysis bullosa), DEB (dystrophic epidermolysis bullosa), SJS ( Stevens-Johnson syndrome), TEN (toxic epidermal necrolysis), radiation induced dermatitis

NDA

FDA meeting

Lomitapide Details
FCS (Familial Chylomicronemia Syndrome)

Phase 2

Data readout